Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs and a licensed national seller of pharmaceutical items in the PRC. Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular disease, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.
Safe Harbor Statement
This press release contains "forward-looking statements" within the
meaning of the "safe-harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include, without limitation,
any statement that may predict, forecast, indicate, or imply future results,
performance or achievements, and may contain the words "estimate," "project,"
"intent," "forecast," "anticipate," "plan," "planning," "expect," "believe,"
"will likely," "should," "could," "would," "may," or words or expressions of
similar meaning. Such statements are not guarantees of future performance and
could cause the actual results of the Company to differ materially from the
results expressed or implied by such statements, including, but not limited to,
changes from anticipated levels of sales, future national or regional economic
and competitive and regulatory conditions, changes in relationships with
customers, access to capital, increased costs, difficulties in developing and
marketing new products, marketing existing products, customer acceptance of
existing and new products, the time to get new drugs approved by the State
Food and Drug Administration and othe
|SOURCE Lotus Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved